Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2017

View Archived Issues

ITUS enters research agreement with Moffitt Cancer Center

European Commission approves Tesaro's Zejula

Genexine's recombinant human erythropoietin effective in patients on dialysis

Selective nSMase2 inhibitor MS-882 shows promise for Alzheimer's disease

Orexo's Zubsolv approved for opioid dependence in Europe

FDA orphan and breakthrough therapy designations awarded to PellePharm for patidegib

FDA grants breakthrough therapy designation to patisiran

Indication for Zytiga expanded in Europe

FDA gives fast track status to lumateperone for treatment of schizophrenia

CX-549's neuroprotective effects demonstrated in a rat model of stroke

OphthaliX completes merger with Wize Pharma

FDA grants orphan drug designation to Revance's daxibotulinumtoxin A for cervical dystonia

Adocia reports phase I results for BioChaperone Glucagon

Melinta Therapeutics presents compounds for treating bacterial infections

Janssen applies to expand indication for Imbruvica in Japan

Novel glucosylceramidase activators presented by Lysosomal Therapeutics

Full U.S. commercial launch for Zilretta

Incyte discloses hPD-1 signaling inhibitors

First patient enrolled in pivotal study of Daiichi Sankyo's DS-8201

EMA announces relocation to the Netherlands

Calliditas Therapeutics gives update on phase III study plans for Nefecon

Calico Life Sciences and AbbVie patent new EIF2B activators

Bayer Pharma identifies vasopressin receptor antagonists

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...